PMID- 16567314
OWN - NLM
STAT- MEDLINE
DCOM- 20060403
LR  - 20131121
IS  - 1769-6917 (Electronic)
IS  - 0007-4551 (Linking)
VI  - 93
IP  - 3
DP  - 2006 Mar 1
TI  - [Treatment of venous thrombosis in cancer patients: practical aspects].
PG  - 271-81
AB  - The risk of venous thromboembolism (VTE) is increased in association with 
      malignancy, and has a potential to produce significant morbidity and mortality. 
      Treatment of such patients with anticoagulants is associated with both benefit 
      and a high rate of complications. In the early phase, the treatment is usually 
      achieved with low molecular weight heparin (LMWH), which has a number of 
      advantages over unfractionated heparin (UFH): once or twice daily administration, 
      no necessary laboratory monitoring, lesser risk of bleeding and no drugs 
      interactions. Nevertheless, the UFH is the anticoagulant of choice when a rapid 
      anticoagulant effect or stop of anticoagulant effect is required, in the 
      treatment of massive pulmonary embolism or severe renal insufficiency. Prolonged 
      anticoagulation with LMWH (over 3 or 6 months) appears to be beneficial on 
      survival for such patients. The subject of anticoagulation in patients with 
      primary or secondary brain tumours is controversial. The long-term 
      anticoagulation mainly use LMWH or vitamin K antagonist. The last ones are more 
      difficult to use because of an unpredictable response with higher rate of 
      recurrence and bleeding. The optimal duration of treatment is not known but the 
      patients should be treated for at least 6 months, even at least 12 months after a 
      second episode of venous thromboembolism. On the primary prevention in high-risk 
      surgical oncology, the LMWH are at least as effective and safer as UFH when the 
      optimal dose was administered. For the medical patients, the use of prophylactic 
      anticoagulant treatment is less clear except the patients who are bedridden for 
      prolonged periods of time. For the secondary prevention, the LMWH seems to be 
      more effective over vitamin K antagonists. For these patients, the anticoagulant 
      therapy is recommended indefinitely or until cancer is resolved.
FAU - Laza-Achille, Mihaela
AU  - Laza-Achille M
AD  - Departement de medecine adulte, Institut Gustave Roussy, 39, rue 
      Camille-Desmoulin, 94800 Villejuif. mihaela_laza@yahoo.com
FAU - Desruennes, Eric
AU  - Desruennes E
FAU - Di Palma, Mario
AU  - Di Palma M
LA  - fre
PT  - English Abstract
PT  - Journal Article
PT  - Review
TT  - Aspects pratiques de la prise en charge des thromboses chez le patient cancereux.
PL  - France
TA  - Bull Cancer
JT  - Bulletin du cancer
JID - 0072416
RN  - 0 (Anticoagulants)
RN  - 0 (Antineoplastic Agents, Hormonal)
RN  - 0 (Heparin, Low-Molecular-Weight)
RN  - 094ZI81Y45 (Tamoxifen)
RN  - 12001-79-5 (Vitamin K)
RN  - 9005-49-6 (Heparin)
SB  - IM
MH  - Anticoagulants/*therapeutic use
MH  - Antineoplastic Agents, Hormonal/adverse effects/therapeutic use
MH  - Heparin/therapeutic use
MH  - Heparin, Low-Molecular-Weight/therapeutic use
MH  - Humans
MH  - Neoplasms/blood/*complications
MH  - Postoperative Complications/prevention & control
MH  - Tamoxifen/adverse effects/therapeutic use
MH  - Thromboembolism/*drug therapy/etiology/prevention & control
MH  - Venous Thrombosis/*drug therapy/etiology/prevention & control
MH  - Vitamin K/antagonists & inhibitors
RF  - 49
EDAT- 2006/03/29 09:00
MHDA- 2006/04/04 09:00
CRDT- 2006/03/29 09:00
PHST- 2005/01/31 00:00 [received]
PHST- 2006/01/04 00:00 [accepted]
PHST- 2006/03/29 09:00 [pubmed]
PHST- 2006/04/04 09:00 [medline]
PHST- 2006/03/29 09:00 [entrez]
PST - ppublish
SO  - Bull Cancer. 2006 Mar 1;93(3):271-81.